Crescent Biopharma, Inc. Total Liabilities
Crescent Biopharma, Inc. total liabilities. Based on the latest financial reports, Crescent Biopharma, Inc. (CBIO) has total liabilities worth $19.50 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CBIO cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Crescent Biopharma, Inc. (2011–2025)
Total liabilities of Crescent Biopharma, Inc. from 2011 to 2025. This chart illustrates how Crescent Biopharma, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Crescent Biopharma, Inc. Competitors by Total Liabilities
The table below lists competitors of Crescent Biopharma, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Capital Bancorp
NASDAQ:CBNK
|
USA | $3.40 Billion |
|
Qingdao Topscomm Commun Inc
SHG:603421
|
China | CN¥1.10 Billion |
|
Solid Power Inc
NASDAQ:SLDP
|
USA | $25.32 Million |
|
Shenzhen Soling Industrial Co Ltd
SHE:002766
|
China | CN¥187.91 Million |
|
Ambassador Hotel Ltd
TW:2704
|
Taiwan | NT$8.09 Billion |
|
EV MOTORS, S.A.
MC:EBROM
|
Spain | €419.19 Million |
|
OPTHEA LTD (SP.ADR/8)
F:UKJ2
|
Germany | €314.48 Million |
|
CellaVision AB
ST:CEVI
|
Sweden | Skr207.31 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Crescent Biopharma, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Crescent Biopharma, Inc. balance sheet assets.
Liquidity & Leverage Metrics
Crescent Biopharma, Inc. Total Liabilities Ratios Explained
Crescent Biopharma, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Crescent Biopharma, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Crescent Biopharma, Inc. (2011–2025)
The table below shows the annual total liabilities of Crescent Biopharma, Inc. from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $37.28 Million | -27.04% |
| 2024-12-31 | $51.10 Million | +640.30% |
| 2023-12-31 | $6.90 Million | -22.28% |
| 2022-12-31 | $8.88 Million | -30.31% |
| 2021-12-31 | $12.74 Million | -12.80% |
| 2020-12-31 | $14.61 Million | +6.13% |
| 2019-12-31 | $13.77 Million | +46.87% |
| 2018-12-31 | $9.38 Million | +5.55% |
| 2017-12-31 | $8.88 Million | +25.32% |
| 2016-12-31 | $7.09 Million | -11.30% |
| 2015-12-31 | $7.99 Million | +23.67% |
| 2014-12-31 | $6.46 Million | +171.90% |
| 2013-12-31 | $2.38 Million | -59.67% |
| 2012-12-31 | $5.89 Million | -71.19% |
| 2011-12-31 | $20.45 Million | -- |
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the develo… Read more